A key gene that fuels the molecular cascade driving prostate cancer bone metastasis progression may open avenues for targeted therapies. With this mda-9 mice model, Fisher and his team observed how ...

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the ...

Breast Cancer Now and Prostate Cancer Research have joined forces to fund up to £600,000 of new research to tackle the spread of both cancers to the bones, known as bone metastasis. Nearly all types ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

In a study published in the journal Genes & Diseases, researchers from Army Medical University and Shenzhen University investigated the pivotal role of miR-18a-5p, a microRNA, in the development and ...

SAN FRANCISCO -- Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy (MDT) in addition to systemic treatment, a meta-analysis of ...

Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate Traditionally, prostate cancer treatment, as well as all cancer treatment, has been designed to target the ...

Weekly docetaxel and estramustine monophosphate (EMP) in the treatment of patients with prostate cancer and persistent/recurrent PSA elevation following primary therapy: A phase II trial of the Minnie ...